67,752 Shares in REGENXBIO Inc. (NASDAQ:RGNX) Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 67,752 shares of the biotechnology company's stock, valued at approximately $484,000. Janney Montgomery Scott LLC owned about 0.14% of REGENXBIO at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in RGNX. Raymond James Financial Inc. acquired a new stake in shares of REGENXBIO in the 4th quarter valued at approximately $568,000. Teacher Retirement System of Texas boosted its holdings in shares of REGENXBIO by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock valued at $97,000 after buying an additional 2,088 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of REGENXBIO by 8.8% in the 4th quarter. American Century Companies Inc. now owns 95,026 shares of the biotechnology company's stock valued at $735,000 after buying an additional 7,658 shares during the last quarter. AXQ Capital LP acquired a new stake in shares of REGENXBIO in the 4th quarter valued at approximately $106,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of REGENXBIO in the 4th quarter valued at approximately $54,000. Institutional investors and hedge funds own 88.08% of the company's stock.

Insiders Place Their Bets

In other news, Director Kenneth T. Mills sold 20,602 shares of REGENXBIO stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $7.91, for a total transaction of $162,961.82. Following the sale, the director directly owned 475,103 shares of the company's stock, valued at approximately $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.79% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on RGNX shares. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a report on Monday, June 9th. HC Wainwright cut their price target on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, March 17th. Leerink Partners set a $24.00 price target on REGENXBIO in a report on Tuesday, March 18th. The Goldman Sachs Group cut their price target on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Finally, Morgan Stanley raised their price target on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX traded down $0.31 during mid-day trading on Monday, reaching $8.43. The company had a trading volume of 679,975 shares, compared to its average volume of 929,241. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $15.36. The firm has a market cap of $422.85 million, a price-to-earnings ratio of -2.71 and a beta of 1.06. The business's 50-day simple moving average is $8.98 and its 200 day simple moving average is $7.88.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The company had revenue of $89.01 million during the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative return on equity of 53.29% and a negative net margin of 100.62%. On average, sell-side analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.